ClinicalTrials.gg
CompletedNCT05818137Updated Jun 10, 2026Results posted

A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

A Phase 3 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed at 17 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Enrollment
9th of 18
46 · median 44
Started
2023
with 2 others
Phase 3
5 of 18
none open now
Registered
8th of 18
by date
Lead sponsor
7 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, and was the 8th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or III while the study includes PAH participants with WHO FC I or IV as other populations. There are no hypotheses for this study.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of World Health Organization (WHO) pulmonary arterial hypertension (PAH) Group 1 in any of the following subtypes:

    • Idiopathic PAH
    • Heritable PAH
    • Drug/toxin-induced PAH
    • PAH associated with connective tissue disease
    • PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair
  • PAH classified as WHO functional class (FC) I or symptomatic PAH classified as WHO FC II to IV
  • On stable doses of background PAH therapy and diuretics (if applicable) for at least 90 days prior to screening

Exclusion criteria

Exclusion Criteria

  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Diagnosis of the following PAH Group 1 subtypes:

    • (HIV)-associated PAH
    • PAH associated with portal hypertension
    • Schistosomiasis-associated PAH
    • PAH with features of significant venous/capillary pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) involvement
  • Is on the waiting list for lung transplant
  • Pregnant or breastfeeding women
  • History of full or partial pneumonectomy
  • Pulmonary function test (PFT) values of forced vital capacity (FVC) \< 60% predicted at the screening visit or within 6 months prior to the screening visit.
  • Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the screening visit or planned initiation during the study.
  • History of more than mild obstructive sleep apnea that is untreated
  • Known history of portal hypertension or chronic liver disease, including and/or (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment.
  • History of restrictive, constrictive, or congestive cardiomyopathy.
  • History of atrial septostomy within 180 days prior to the screening visit.
  • Personal or family history of long syndrome (LQTS) or sudden cardiac death.
  • (LVEF) \< 45% on historical Echocardiogram (ECHO) within 6 months prior to the screening visit.
  • Any symptomatic coronary disease events within 6 months prior to the screening visit.
  • Cerebrovascular accident within 3 months prior to the screening visit.
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease, mitral stenosis and more than mild aortic valve stenosis.
  • Prior exposure to sotatercept or luspatercept or history of allergic or anaphylactic reaction or to recombinant proteins or in product
  • Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to the screening visit
  • Currently enrolled in or have completed any other investigational product study within 30 days
  • Weight at the screening is over 85 kg
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Sotatercept

    Participants on background PAH therapy will receive sotatercept subcutaneous (SC) injections at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 3 weeks up to 24 weeks. Thereafter, participants may choose to receive the sotatercept treatment at same dose and schedule in the extension treatment period from Week 24 until up to 6 months after sotatercept becomes locally commercially available and reimbursed in Japan.

    Biological: Sotatercept

Interventions

  • BiologicalSotatercept

    SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.

    Also known as: MK-7962, ActRIIA-IgG1Fc, ACE-011

06

What researchers measure

Primary outcomes

  1. Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24

    PVR was the resistance against blood flow from the pulmonary artery to the left atrium. PVR was measured in dyn\*sec/cm\^5 by right heart catheterization (RHC). RHC was performed during the screening period (baseline) and Week 24. Per protocol, the change in PVR from baseline at Week 24 was reported for the primary treatment period.

    Time frame: Baseline and Week 24

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Per protocol, the number of participants who experienced an AE were reported for the primary treatment period.

    Time frame: Up to ~24 weeks

  3. Number of Participants Who Discontinued Study Intervention Due to AEs

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Per protocol, the number of participants who discontinued study treatment due to AEs were reported for the primary treatment period.

    Time frame: Up to ~24 weeks

Secondary outcomes

  1. Change From Baseline in Six-Minute Walk Distance (6MWD) at Week 24

    The 6MWD was the distance walked in 6 minutes as a measure of functional capacity was measured during the screening period (baseline) and at Week 24. This was assessed using the 6-minute walk test (6MWT). Per protocol, the change from baseline in 6MWD at Week 24 was reported for the primary treatment period.

    Time frame: Baseline and Week 24

  2. Percentage of Participants With Improvement in World Health Organization Functional Class (WHO FC) at Week 24

    The severity of participant's pulmonary arterial hypertension (PAH) symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. Per protocol, the percentage of participants with improvement in WHO FC at Week 24 were presented for the primary treatment period.

    Time frame: Baseline and Week 24

  3. Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 24

    NT-proBNP is an established marker of ventricular dysfunction in participants with PAH. NT-proBNP was measured at Day 1 (baseline) and at Week 24. The change from baseline in NT-proBNP at Week 24 was reported for the primary treatment period.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 27, 2025

Participant flow

Primary Treatment Period
Participant flow — Primary Treatment Period
MilestoneSotatercept
Started46
Completed46
Not completed0
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneSotatercept
Started45
Completed0
Not completed45
Withdrew: Withdrawal by subject1
Withdrew: Ongoing participants44

Outcome measures

PrimaryChange From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24

PVR was the resistance against blood flow from the pulmonary artery to the left atrium. PVR was measured in dyn\*sec/cm\^5 by right heart catheterization (RHC). RHC was performed during the screening period (baseline) and Week 24. Per protocol, the change in PVR from baseline at Week 24 was reported for the primary treatment period.

Time frame:
Baseline and Week 24
Reported as:
Median · dynes*sec/cm^5
Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24
dynes*sec/cm^5Sotatercept - Primary Treatment Period
Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24417.2 (235.2 to 812.8)
Statistical analysis
  • Sotatercept - Primary Treatment Period · Change from baseline estimate: -99.2 · 95% CI -129.6 to -68.4The change from baseline estimate and associated 95% confidence interval (CI) based on the Hodges-Lehmann method.
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Per protocol, the number of participants who experienced an AE were reported for the primary treatment period.

Time frame:
Up to ~24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsSotatercept - Primary Treatment Period
Number of Participants Who Experienced an Adverse Event (AE)43
PrimaryNumber of Participants Who Discontinued Study Intervention Due to AEs

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Per protocol, the number of participants who discontinued study treatment due to AEs were reported for the primary treatment period.

Time frame:
Up to ~24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to AEs
ParticipantsSotatercept - Primary Treatment Period
Number of Participants Who Discontinued Study Intervention Due to AEs0
SecondaryChange From Baseline in Six-Minute Walk Distance (6MWD) at Week 24

The 6MWD was the distance walked in 6 minutes as a measure of functional capacity was measured during the screening period (baseline) and at Week 24. This was assessed using the 6-minute walk test (6MWT). Per protocol, the change from baseline in 6MWD at Week 24 was reported for the primary treatment period.

Time frame:
Baseline and Week 24
Reported as:
Median · Meter
Change From Baseline in Six-Minute Walk Distance (6MWD) at Week 24
MeterSotatercept - Primary Treatment Period
Change From Baseline in Six-Minute Walk Distance (6MWD) at Week 24462.0 (305.0 to 560.0)
Statistical analysis
  • Sotatercept - Primary Treatment Period · Change from baseline estimate: 41.8 · 95% CI 27.8 to 55.5The change from baseline estimate and associated 95% confidence interval (CI) based on the Hodges-Lehmann method.
SecondaryPercentage of Participants With Improvement in World Health Organization Functional Class (WHO FC) at Week 24

The severity of participant's pulmonary arterial hypertension (PAH) symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. Per protocol, the percentage of participants with improvement in WHO FC at Week 24 were presented for the primary treatment period.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement in World Health Organization Functional Class (WHO FC) at Week 24
Percentage of participantsSotatercept - Primary Treatment Period
Percentage of Participants With Improvement in World Health Organization Functional Class (WHO FC) at Week 2419.6 (9.4 to 33.9)
SecondaryChange From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 24

NT-proBNP is an established marker of ventricular dysfunction in participants with PAH. NT-proBNP was measured at Day 1 (baseline) and at Week 24. The change from baseline in NT-proBNP at Week 24 was reported for the primary treatment period.

Time frame:
Baseline and Week 24
Reported as:
Median · pg/mL
Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 24
pg/mLSotatercept - Primary Treatment Period
Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 2418.5 (18.5 to 1471.0)
Statistical analysis
  • Sotatercept - Primary Treatment Period · Change from baseline estimate: -48.5 · 95% CI -77.0 to -24.8The change from baseline estimate and associated 95% confidence interval (CI) based on the Hodges-Lehmann method.

Adverse events

Collected over Up to approximately 42 weeks (Primary treatment period: Weeks 1-24 & extension Treatment Period: Weeks 24-42). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept - Primary Treatment Period0/46 (0%)6/46 (13%)36/46 (78.3%)
Sotatercept - Extension Treatment Period0/45 (0%)2/45 (4.4%)12/45 (26.7%)
Most frequent serious events
Most frequent serious events
EventSotatercept - Primary Treatment PeriodSotatercept - Extension Treatment Period
NasopharyngitisInfections and infestations0/461/45
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders0/461/45
Large intestine polypGastrointestinal disorders1/460/45
BacteraemiaInfections and infestations1/460/45
Catheter site infectionInfections and infestations1/460/45
HypocalcaemiaMetabolism and nutrition disorders1/460/45
Loss of consciousnessNervous system disorders1/460/45
Device physical property issueProduct Issues1/460/45
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSotatercept - Primary Treatment PeriodSotatercept - Extension Treatment Period
NasopharyngitisInfections and infestations14/467/45
HeadacheNervous system disorders10/461/45
Haemoglobin increasedInvestigations8/463/45
EpistaxisRespiratory, thoracic and mediastinal disorders8/465/45
VertigoEar and labyrinth disorders3/460/45
DiarrhoeaGastrointestinal disorders3/460/45
MalaiseGeneral disorders3/460/45
PyrexiaGeneral disorders3/460/45
COVID-19Infections and infestations3/460/45
ArthralgiaMusculoskeletal and connective tissue disorders3/460/45

Baseline characteristics

All allocated participants.

Age, Continuous
Age, Continuous(Years)Sotatercept
Mean44.7 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept
Female34
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotatercept
Hispanic or Latino0
Not Hispanic or Latino46
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept
American Indian or Alaska Native0
Asian46
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Pulmonary Vascular Resistance (PVR) at Baseline
Pulmonary Vascular Resistance (PVR) at Baseline(Participants)Sotatercept
≤800 dyn*sec/cm^543
>800 dyn*sec/cm^53
08

Study locations

17 sites
  • Nagoya University Hospital ( Site 2010)
    Nagoya, Aichi-ken 466-8560, Japan
  • Chiba Saiseikai Narashino hospital ( Site 2004)
    Narashino, Chiba 275-8580, Japan
  • Kurume University Hospital ( Site 2014)
    Kurume, Fukuoka 830-0011, Japan
  • Kure Kyosai Hospital ( Site 2017)
    Kure, Hiroshima 7378505, Japan
  • Sapporo Medical University Hospital ( Site 2018)
    Sapporo, Hokkaido 060-8543, Japan
  • Hokkaido University Hospital ( Site 2001)
    Sapporo, Hokkaido 060-8648, Japan
  • Kobe University Hospital ( Site 2012)
    Kobe, Hyōgo 650-0017, Japan
  • Tohoku University Hospital ( Site 2002)
    Sendai, Miyagi 980-8574, Japan
  • National Cerebral and Cardiovascular Center ( Site 2011)
    Suita, Osaka 564-8565, Japan
  • Hamamatsu University Hospital ( Site 2016)
    Hamamatsu, Shizuoka 431-3192, Japan
  • The University of Tokyo Hospital ( Site 2006)
    Bunkyo-ku, Tokyo 113-8654, Japan
  • Kyorin University Hospital ( Site 2005)
    Mitaka, Tokyo 181-8611, Japan
  • Chiba University Hospital ( Site 2003)
    Chiba, 260-8677, Japan
  • Kyushu University Hospital ( Site 2015)
    Fukuoka, 812-8582, Japan
  • National Hospital Organization Okayama Medical Center ( Site 2013)
    Okayama, 701-1192, Japan
  • International University of Health and Welfare Mita Hospital ( Site 2008)
    Tokyo, 108-8329, Japan
  • Keio university hospital ( Site 2007)
    Tokyo, 1608582, Japan
09

References and documents

Publications

  • Matsubara H, Tanabe N, Ogo T, Abe K, Inami T, Maeda Y, Arano I, Shirakawa M, Sakai R, Cornell AG; Sotatercept Study 020 Investigators. Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension. JACC Asia. 2026 Mar;6(3):297-309. doi: 10.1016/j.jacasi.2025.12.009. Epub 2026 Jan 31. PubMed 41618947 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Mar 2024, 10 months.

Results were first posted in Feb 2025, 11 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 10 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Apr 18, 2023
StartActual
May 10, 2023
Primary completionActual
Mar 12, 2024
CompletionActual
Nov 6, 2025
Results first posted
Feb 27, 2025
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05818137
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
May 10, 2023
Primary completion
Mar 12, 2024
Completion
Nov 6, 2025
Results posted
Feb 27, 2025
Last update
Jun 10, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion